Compelling presentation by Tamim Niazi! DASL-HiCaP: adding darolutamide to ADT + RT improved MFS in very high-risk nonmetastatic prostate cancer (HR 0.42; 4-year MFS 95% vs 88%). I

Toni Choueiri, MD· @DrChoueiri · X·2026-10-25 00:06· 23 hours agoScore90

Body

Compelling presentation by Tamim Niazi! DASL-HiCaP: adding darolutamide to ADT + RT improved MFS in very high-risk nonmetastatic prostate cancer (HR 0.42; 4-year MFS 95% vs 88%). Important phase III evidence for intensification! #ESMO26 @oncoalert @myESMO

524 views · 16 likes · 10 reposts · 0 replies

Conference abstracts

LBA1matched by Presidential Symposium I

INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)

https://esmocongress.esmo.org

LBA2matched by Presidential Symposium I

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org

LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

LBA4matched by Presidential Symposium I

Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t

https://esmocongress.esmo.org

Source: Toni Choueiri, MD · x.com